AUS
NZ
UK
CA
USA
IND
Eve Health Group Limited (ASX:EVE) has informed the market that 810,000 unquoted Options have lapsed following failure to satisfy the conditions attached to these securities. These options, with an exercise price of $0.06 and an original expiry date of 31 December 2028, expired early on 30 June 2026 after the vesting conditions were not met and became impossible to fulfill. The company confirmed that no consideration was paid upon their cessation, resulting in a reduction of Eve Health Group's total unquoted option pool. Investors monitoring the company’s Capital Structure will note the updated Issued Capital figures now reported by the company.
Key Points
- Company: Eve Health Group Limited (ASX:EVE)
- 810,000 unquoted options (ASX Code: EVEAI) have lapsed due to unmet vesting conditions
- Options carried a $0.06 exercise price and were originally set to expire on 31 December 2028; cessation occurred on 30 June 2026
- No payment was made by the company in relation to the lapse
- Total fully paid ordinary shares remain at 352,326,592 after this change
- Investors should monitor any future updates regarding Eve Health Group’s option pool or capital structure
810,000 EVEAI Options Expire Early Due to Failure to Meet Vesting Conditions
On 1 July 2026, Eve Health Group Limited filed an Appendix 3H with the ASX, formally announcing that 810,000 options with the ASX code EVEAI ceased on 30 June 2026. The filing explained that the lapse occurred because the conditions tied to these options were either unmet or became impossible to satisfy. This process aligns with ASX Listing Rules that require options linked to performance or service conditions to be extinguished if those conditions cannot be fulfilled.
The lapsed options were identified as "OPTION EXPIRING 31-DEC-2028 EX $0.06," granting holders the right to acquire Eve Health Group ordinary shares at $0.06 each until the original expiry date. The early termination on 30 June 2026, over two years before expiration, indicates the relevant tranche’s conditions failed or became unachievable by that date. The company confirmed no compensation was paid to holders upon lapse.
Implications of the Lapsed Options for Holders
When options lapse due to unmet conditions, holders lose the right to exercise them and purchase shares at the specified price. In this case, the 810,000 options at $0.06 each represented a potential acquisition of shares valued at $48,600 if fully exercised. Because the conditions were not met, this potential dilution is eliminated, and holders receive no compensation. The company did not disclose the identities of the option holders, the specific conditions that failed, or reasons for their impossibility to be satisfied.
From an investor standpoint, the lapse of conditional options is generally neutral to mildly positive for existing shareholders as it removes a potential dilution source without any cash outflow. However, it may also indicate that performance targets, employment criteria, or other milestones linked to these options were not achieved. The company provided no additional commentary beyond the regulatory disclosure.
Revised Unquoted Option Pool Following the EVEAI Option Lapse
After the lapse of 810,000 EVEAI options, the Appendix 3H filing details the updated capital structure for Eve Health Group. The EVEAI option class, which includes options expiring 31 December 2028 at $0.06 exercise price, now totals 6,490,000 options, reduced from the prior total that included the lapsed options.
The company’s remaining unquoted equity securities include three other option classes: 130,400,000 options expiring 30 April 2028 at $0.04 (code: EVEAJ); 5,000,000 options expiring 30 April 2029 at $0.04 (code: EVEAK); and 22,999,998 options expiring 31 December 2027 at $0.06 (code: EVEAH). Collectively, Eve Health Group maintains a large unquoted option pool that could significantly increase the company’s share count if fully exercised in the future.
Ordinary Share Count Remains Steady at 352,326,592
The Appendix 3H confirms that the lapse of the 810,000 EVEAI options does not affect Eve Health Group’s ordinary fully paid share count, which remains at 352,326,592 shares. The option lapse does not involve issuing or cancelling shares; it simply removes the holders’ future right to convert options into ordinary shares under the original terms.
This share count figure is used by the ASX to calculate the company’s market capitalisation. Investors tracking Eve Health Group’s market cap and dilution should note the modest reduction in unquoted options due to this lapse, though the remaining approximately 164.9 million unquoted options across four active classes still represent potential future dilution if exercised.
Overview of the Appendix 3H Filing Process Under ASX Rules
An Appendix 3H is a mandatory ASX form filed by listed entities to notify the market when securities cease to exist—whether by expiry, lapse, cancellation, or other means. This ensures transparency regarding changes in issued capital and maintains accurate ASX records for market capitalisation calculations and investor information.
In this case, Eve Health Group lodged the filing on 1 July 2026, the business day following the 30 June 2026 cessation, complying with ASX prompt notification requirements. The filing includes a standard disclaimer that figures in Parts 3.1 and 3.2 are automatically generated and may not reflect the current issued capital if other related forms are processed simultaneously.
No Consideration Paid for the Option Lapse
The filing confirms that Eve Health Group did not pay any consideration for the cessation of the options. This aligns with typical market practice where options lapse due to unmet conditions; unlike buybacks or cancellations, such lapses do not involve payments to holders.
Consequently, the lapse has no direct cash flow impact or accounting liability for the company. No additional information or management commentary was provided beyond the standard regulatory disclosure.
Summary of Eve Health Group’s Option Exercise Prices and Expiry Dates
Following the formal lapse of EVEAI options, investors can see the remaining option classes: the largest is the EVEAJ tranche with 130,400,000 options exercisable at $0.04, expiring 30 April 2028. This class poses the greatest potential dilution risk due to its volume and lower exercise price compared to other classes.
The EVEAH class includes 22,999,998 options at $0.06 expiring 31 December 2027, and the remaining EVEAI class holds 6,490,000 options at $0.06 expiring 31 December 2028. The smallest tranche is EVEAK with 5,000,000 options at $0.04 expiring 30 April 2029. The company did not disclose any remaining vesting conditions on these classes.
Investor Outlook on Eve Health Group’s Capital Structure Post-Update
For investors, this update indicates a slight reduction in potential dilution from the unquoted option pool. While 810,000 options are a small portion compared to the 130.4 million EVEAJ options, the formal lapse ensures the company’s capital records remain accurate.
The filing is a routine compliance disclosure and did not appear to impact the share price significantly. Investors should watch for future disclosures about the performance and vesting status of remaining options, as well as any strategic or operational news that could influence the share price relative to option exercise prices.
Upcoming Option Expiries and Capital Events to Monitor
The next notable option expiry is the EVEAH class on 31 December 2027, covering 22,999,998 options at $0.06. Prior to that, the large EVEAJ class expiring 30 April 2028 will be critical for dilution analysis. Changes in the company’s share price relative to these exercise prices could lead to option exercises or further lapses, affecting share count and market capitalisation.
Beyond the option register, investors should look for operational and financial updates that reveal Eve Health Group’s business progress. This filing does not include information on revenues, earnings, strategic plans, or management commentary. Future company announcements will provide insight into the company’s advancement toward its corporate goals.
